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and matched for age, gender and geographic location. The index date was defined 
as the date of the first AD diagnosis or the first script for AD medication whichever 
comes first. Prevalence of diseases and treatment exposures in the years preceding 
the index date were analyzed according to the occurrence of diseases (ICD-9 codes) 
and medication utilization (AHFS codification) between AD patients and the control 
group. Results: Data were obtained for a random sample of 34,086 AD patients 
(mean age of 78.5 years [SD= 8.0], 65.2% females). A higher proportion of patients 
had a diagnosis of organic psychotic conditions (49.6% vs. 9.2%, p< 0.001), other 
psychoses (21.9% vs. 8.6%, p< 0.001) and neurotic disorders, personality disorders 
and other nonpsychotic mental disorders (69.1% vs. 55.4%, p< 0.001) in the AD group 
compared to the control group. Furthermore, a greater number of patients used psy-
chotropic drugs (53.5% vs. 35.9%, p< 0.001) and anxiolytics, sedatives and hypnotics 
(70.3% vs. 65.9%, p< 0.001) in the AD group than in the control group. ConClusions: 
Comorbidities’ frequency was higher in AD patients for several diseases and treat-
ments, particularly for mental disorders-related diagnoses and medications.
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objeCtives: To estimate the efficacy of fingolimod versus placebo on confirmed 
disability progression (CDP) and on time to severe disability health states in 
patients with relapsing–remitting multiple sclerosis (RRMS) failing prior treat-
ment. Methods: Patients failing prior treatment were defined as: 1) ≥ 1 relapse 
in the previous year and either ≥ 1 gadolinium-enhancing T1 lesion or a T2 lesion 
count ≥ 9 at baseline, or 2) equal or more relapses in the year prior to baseline 
compared with the previous year. Hazard ratios (HR) for 3-month and 6-month CDP, 
measured using Expanded Disability Status Scale (EDSS) scores, were estimated 
using Cox proportional hazards models. Both per-protocol definitions of CDP and 
revised definitions used in other trials were analysed. Time from EDSS score 0 to 
scores of 4 or 6 and to conversion to secondary progressive MS (SPMS) were esti-
mated by fitting a multi-state Markov Transition model to individual patient data 
from the pooled FREEDOMS placebo groups (HRs accounted for treatment effects) 
and the London Ontario cohort (SPMS and RRMS–SPMS transitions). Results: 
Using both definitions of treatment failure, fingolimod reduced the risk of 3-month 
CDP (per-protocol) by 35% (definition 1: HR: 0.65; p< 0.05) and 34% (definition 2: 
HR: 0.66; p< 0.05) versus placebo. The corresponding HRs for 6-month CDP were 
0.61 (p= 0.06) and 0.60 (p< 0.05). HRs were generally lower using the revised CDP 
definition. The Markov Transition model, assuming a 40% reduction, estimated 
that fingolimod delays the median time to EDSS 4 (2.2 years, 61% increase), EDSS 
6 (3.3 years, 52% increase) and SPMS (4.5 years, 62% increase) compared with pla-
cebo. ConClusions: Fingolimod is highly efficacious in delaying CDP in patients 
failing prior treatment, and our modeling approach suggests that this translates 
into a meaningful delay in time to severe disability health states.
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objeCtives: As the number of available disease-modifying therapies (DMT) for 
relapsing-remitting multiple sclerosis (RRMS) expands, consideration of all evidence 
on comparative efficacy of newer second generation therapies with established 
first generation therapies is required to inform clinical care and health policy. This 
network meta-analysis (NMA) estimates the relative efficacy of DMT in reducing 
relapses and slowing short-term progression of disability in RRMS. Methods: A 
systematic review of RCTs of interferon-beta, glatiramer acetate (first generation 
DMTs), natalizumab, alemtuzumab, fingolimod, teriflunomide, laquinimod, and 
BG-12 (second generation DMTs) compared with each other or with placebo for the 
treatment of RRMS, identified 20 eligible RCTs (n= 14610). A random-effects NMA 
model was used to calculate relative annualized relapse rate (ARR) and hazard 
ratio (HR) of short-term disability progression. Results: Statistically significant 
reductions in ARR versus placebo, between 24% - 69% for second generation DMTs 
and 16% - 33% for first generation DMTs were found. Alemtuzumab, natalizumab, 
fingolimod, and BG-12 were significantly more efficacious than other DMTs in 
reducing ARR. There was greater uncertainty associated with DMT efficacy in reduc-
ing short-term disability progression. Significant improvements over placebo in 
reducing short-term disability progression were restricted to second generation 
DMTs alemtuzumab, natalizumab, fingolimod, laquinimod, BG-12, and terifluno-
mide 14mg (HR 0.27 - 0.54). No statistically significant improvements in short-term 
disability progression were exhibited by first generation DMTs and teriflunomide 
7mg. ConClusions: The growing number of innovative second generation DMTs 
offers the potential of therapeutic advances in reducing relapse rates in RRMS, with 
less certain benefits on short-term disability progression. Despite these potential 
advantages, the relative position of second generation DMTs on the RRMS treatment 
landscape remains to be defined, due to potentially serious side effects, limited 
long-term safety data and their high cost.
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disagree that innovation in health care is worthwhile; the tremendous technological 
success in pharmacological treatment of HIV patients is a case in point. On the other 
hand, a relatively large number of “me-too” entries in the pharmaceutical market 
and the diminishing productivity of R&D sector call for robust methodologies, which 
could distinguish high-value, breakthrough products. Sensitivity analyses of cost-
effectiveness studies should be made pivotal in decision-making process in order 
to ensure efficient diffusion of innovation.
Prm243
survEy DEsigN iN tHE assEssmENt of tHE imPlEmENtatioN of risk 
miNimisatioN mEasurEs for mEDiciNal ProDucts
Prieto L., Hidalgo-Simon A., Arlett P.
European Medicines Agency, London, UK
The introduction of the risk management plan (RMP) has ensured greater proactivity 
to the pharmacovigilance and post-authorisation benefit risk assessment of human 
medicines. An RMP may include risk minimisation measures (RMM), public health 
interventions intended to prevent the occurrence, or reduce the impact of adverse 
drug reactions associated with the exposure to a drug. The new EU legislation on 
pharmacovigilance explicitly requires the active monitoring of the outcome of RMM, 
placing obligations on regulators and industry for this purpose. In this respect, the 
European Medicines Agency’s good pharmacovigilance practices module dedicated 
to the practical implementation of the legislation on the evaluation of the effective-
ness of RMM foresees a dual evidence approach. This approach builds on the assess-
ment of two distinct levels of evidence: the actual implementation of the RMM, and 
the attainment of its final objective(s). The approach requires research encompass-
ing analysis of implementation (process indicators), and traditional epidemiological 
research addressing the attainment (final outcome indicators) of RMM. Surveys 
are usually involved in the assessment of process indicators, in particular when 
RMM imply the provision of educational information to health care professionals 
(HCP) and the surveys are intended to measure what the HCP have learned. This 
paper aims to conceptualise the construction of surveys designed for the analysis of 
implementation of RMM. Such surveys should be developed following the principles 
of content validation. This requires a body of relevant questions (items), the sample 
population to which it will be administered, and a test plan. The test plan includes 
the type of items to be used, the number of items, the length of administration, 
how it is to be administered, and how it is to be scored and analysed in terms of 
item difficulty and discrimination. The paper concludes with a checklist to assist 
stakeholders in designing surveys for RMM assessment purposes.
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objeCtives: To summarize literature on the burden of epilepsy in tuberous sclero-
sis complex (TSC); TSC is a genetic disease characterized by behavioral disorders, 
benign tumors in multiple organs, and neurological manifestations including epi-
lepsy. Methods: A systematic search of keywords for TSC and burden of illness 
was conducted in MEDLINE- and EMBASE-indexed publications from 5/2000-1/2013, 
and non-indexed materials. Results: In total, 83 articles on TSC-associated epi-
lepsy were included. Up to 93% of TSC patients have epilepsy, with severe forms 
more common than in non-TSC epilepsy patients (infantile spasms, 35-57% vs. 9%; 
generalized tonic-clonic or grand mal seizures, 37% vs. 7%; complex focal seizures, 
87% vs. 33%). Seizure onset is early (median age: 7 months, 82% by age 3). TSC2 
gene mutations and cortical tubers, common brain malformations in TSC, are risk 
factors for early onset and greater severity of seizures. TSC-epilepsy patients have 
significant disabilities, including high rates of autism spectrum disorders (13-30%) 
and cognitive impairment/delay (62-80%). Although data are not available on long-
term outcomes, early seizure control may reduce cognitive impairment and autism 
symptoms. Vigabatrin is a first-line treatment option for TSC-associated infantile 
spasms and focal seizures in infants, but poses a risk of serious retinal toxicity. 
Other anti-epileptic drugs are available as second-line options; most patients still 
require polytherapy, and 62% have refractory epilepsy that can necessitate surgery. 
With high rates of medication use, hospitalizations, and surgeries, TSC-epilepsy 
patients may consume substantial health care resources, particularly during the 
first 5 years post-diagnosis. Longitudinal trends in resource use, direct and indirect 
costs, and treatment patterns for TSC-epilepsy are largely absent from the litera-
ture. ConClusions: TSC-epilepsy is common and may be severe, with presenta-
tion early in childhood and long-term morbidity. True disease burden to patients, 
caregivers, and payers remains unknown given substantial data gaps in longitudinal 
clinical outcomes, treatment patterns, and costs.
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objeCtives: To identify potential determinants of Alzheimer’s disease (AD) by ana-
lyzing past medical history in terms of previous diseases or treatment exposures 
of patients with AD compared to patients without the disease, using the Quebec 
provincial drug reimbursement program database (RAMQ). Methods: This ret-
rospective study included patients covered by the RAMQ who had at least one 
diagnosis of AD (ICD-9 code 3310) or have received at least one script for an AD 
medication (donepezil, rivastigmine, galantamine or memantine) from January, 1985 
to December, 2011. A control group of patients without AD was created on a 1:1 ratio 
